[1]魏丽丽,郝瑞卿,王华瑛.KPNA2在乳腺癌组织中的表达及临床病理意义[J].医学信息,2022,35(18):53-56.[doi:10.3969/j.issn.1006-1959.2022.18.012]
　WEI Li-li,HAO Rui-qing,WANG Hua-ying.The Expressions of KPNA2 in the Breast Cancer and its Clinicopathological Significance[J].Journal of Medical Information,2022,35(18):53-56.[doi:10.3969/j.issn.1006-1959.2022.18.012]
点击复制

KPNA2在乳腺癌组织中的表达及临床病理意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
53-56
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
The Expressions of KPNA2 in the Breast Cancer and its Clinicopathological Significance
文章编号:
1006-1959（2022）18-0053-04
作者:
魏丽丽; 郝瑞卿; 王华瑛
（昌邑市妇幼保健院病理科1，儿科2，妇科3，山东 昌邑 261300）
Author(s):
WEI Li-li; HAO Rui-qing; WANG Hua-ying
(Department of Pathology1,Department of Pediatrics2,Department of Gynecology3,Changyi Maternal and Child Care Hospital,Changyi 261300,Shandong,China)
关键词:
乳腺癌; 临床病理参数; KPNA2; β-catenin; cyclinD1
Keywords:
Breast cancer; Clinicopathological parameter; KPNA2; β-catenin; cyclinD1
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2022.18.012
文献标志码:
A
摘要:
目的 探讨KPNA2、β-catenin及cyclinD1在乳腺癌中的表达及临床病理意义。方法 选取我院2014年1月-2019年8月未经放化疗的乳腺浸润性导管癌标本120例设为实验组，另选取50例实验组的距离癌旁1 cm的正常乳腺组织作为对照组。采用免疫组化方法检测组织中KPNA2、β-catenin及cyclinD1的表达情况，分析KPNA2、β-catenin及cyclinD1与乳腺癌临床病理参数及预后的关系。结果 KPNA2、β-catenin、CyclinD1在乳腺癌中高表达率分别为53.30%、49.10%、50.80%，呈明显高表达（P＜0.05）；KPNA2、β-catenin及cyclinD1的表达与组织学级别、淋巴结转移、TNM分期、Ki-67指数相关（P＜0.05），与ER、PR、HER-2的表达、肿瘤大小及年龄无关（P＞0.05）；KPNA2的表达分别与β-catenin（r=0.350，P=0.010）、cyclinD1（r=0.370，P=0.010）呈正相关，β-catenin的表达与cyclinD1的表达呈正相关（r=0.320，P=0.030）；通过TCGA数据库得知，KPNA2高表达乳腺癌患者预后不良。结论 KPNA2、β-catenin及cyclinD1的表达与乳腺癌的恶性程度、高侵袭性及增殖指数高有关。KPNA2高表达提示乳腺癌患者预后不良，可能用于临床预后指导，其作用于乳腺癌的发生发展机制可能与Wnt通路相关。
Abstract:
Objective To investigate the expression and clinicopathological significance of KPNA2, β-catenin and cyclinD1 in breast cancer.Methods A total of 120 cases of breast invasive ductal carcinoma without radiotherapy and chemotherapy in our hospital from January 2014 to August 2019 were selected as the experimental group, and 50 cases of normal breast tissue 1 cm away from the paracancerous tissue were selected as the control group. The expression of KPNA2, β-catenin and cyclinD1 was detected by immunohistochemistry. The relationship between the expression of KPNA2, β-catenin, cyclinD1 and clinicopathological parameters and prognosis of breast cancer was analyzed.Results The high expression rates of KPNA2, β-catenin and CyclinD1 in breast cancer were 53.30%, 49.10% and 50.80%, respectively, which were significantly higher (P<0.05). The expression of KPNA2, β-catenin and cyclinD1 was correlated with histological grade, lymph node metastasis, TNM stage and Ki-67 index (P<0.05), but not with ER, PR, HER-2 expression, tumor size and age (P>0.05). The expression of KPNA2 was positively correlated with β-catenin (r=0.350, P=0.010) and cyclinD1 (r=0.370, P=0.010); the expression of β-catenin was positively correlated with cyclinD1 (r=0.320, P=0.030). According to the TCGA database, breast cancer patients with high KPNA2 expression have a poor prognosis.Conclusion The expression of KPNA2, β-catenin and cyclinD1 is related to the malignant degree, high invasiveness and high proliferation index of breast cancer. The high expression of KPNA2 suggests that the prognosis of breast cancer patients is poor, which may be used for clinical prognosis guidance. The mechanism of its role in the occurrence and development of breast cancer may be related to the Wnt pathway.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]DeSantis CE,Miller KD,Goding Sauer A,et al.Cancer statistics for African Americans, 2019 [J].CA Cancer J Clin,2019,69(3):211-233.[3]陈万青,郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床,2015,42(13):668-674.[4]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2019 [J].CA Cancer J Clin,2019,69(1):7-34.[5]Christiansen A,Dyrskjot L.The functional role of the novel biomarker karyopherin alpha 2 (KPNA2) in cancer[J].Cancer Lett,2013,33(1):18-23.[6]Zhou LN,Tan Y,Li P,et al.Prognostic value of increased KPNA2 expression in some solid tumors: A systematic review and meta-analysis[J].Oncotarget,2017,8(1):303-314.[7]Huang JX,Wu YC,Cheng YY,et al.IRF1 Negatively Regulates OncogenicKPNA2Expression Under Growth Stimulation and Hypoxia inLung CancerCells[J].Onco Targets Ther,2019,12(1):11475-11486.[8]Guo X,Wang Z,Zhang J, et al.Yoshitake K, Tanaka S, Mogushi K,Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types[J].Acta Biochim Biophys Sin (Shanghai),2019,51(3):285-292.[9]Müller T,Tolkach Y,Stahl D,et al.Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma[J].Clin Genitourin Cancer,2019,17(1):e167-e175.[10]Wang CI,Yu CJ,Huang Y,et al.Association of overexpressed karyopherin alpha 2 with poor survival and its contribution to interleukin-1β-induced matrix metalloproteinase expression in oral cancer[J].Head Neck,2018,40(8):1719-1733.[11]Zhang Q,Jin X,Shi W,et al.A long non-coding RNA LINC00461-dependent mechanism underlying breast cancer invasion and migration via the miR-144-3p/KPNA2 axis[J].Cancer Cell Int,2020,20(1):137.[12]Duan M,Hu F,Li D,et al.Silencing KPNA2 inhibits IL-6-induced breast cancer exacerbation by blocking NF-κB signaling and c-Myc nuclear translocation in vitro[J].Life Sci,2020,30(1):253.[13]Ma S,Zhao X.KPNA2 is a promising biomarker candidate for esophageal squamous cell carcinoma and correlates with cell proliferation [J].Oncology Reports,2014,32(1):1631-1637.[14]Li C,Ji L,Ding ZY,et al.Overexpression of KPNA2 correlates with poor prognosis in patients with gastric adenocarcinoma[J].Tumour Biology,2013,34(3):1021-1026.[15]Zhang Y,Zhang M,Yu F,et al.Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer[J].Journal of Experimental & Clinical Cancer Research,2015,34(1):145.[16]Gao L,Yu L,Li CM,et al.Karyopherin α2 induces apoptosis in tongue squamous cell carcinoma CAL-27 cells through the p53 pathway[J].Oncol Rep,2016,35(6):3357-3362.[17]Li J,Liu Q,Liu Z,et al.KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc [J].J Exp Clin Cancer Res,2018,37(1):194.[18]Erben PB,Brunner K,Hecht M,et al.Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome [J].Int J Clin Exp Pathol,2015,8(12):15814-15824.[19]Wang Y,Lei L,Zheng YW,et al.Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and β-catenin [J].Cancer Sci,2018,109(6):1799-1810.[20]Bjelic-Radisic V,Fitzal F,Knauer M,et al.Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial[J].BMC Cancer,2020,20(1):392.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(18):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[3]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Journal of Medical Information,2018,31(18):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[4]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Journal of Medical Information,2018,31(18):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[5]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
　ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Journal of Medical Information,2018,31(18):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[6]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
　ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(18):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[7]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Journal of Medical Information,2018,31(18):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[8]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,31(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
　QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Journal of Medical Information,2018,31(18):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[9]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
　ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Journal of Medical Information,2018,31(18):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[10]张 乐,徐胜昔,郭翔取,等.Tyrer-Cuzick模型联合SNPs位点在江西地区乳腺癌诊断中应用研究[J].医学信息,2018,31(24):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]
　ZHANG Le,XU Sheng-xi,GUO Xiang-qu,et al.Application of Tyrer-Cuzick Model Combined with SNPs Locus in the Diagnosis of Breast Cancer in Jiangxi Area[J].Journal of Medical Information,2018,31(18):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]

更新日期/Last Update: 1900-01-01